On February 28, 2019 Incyte Corporation (Nasdaq:INCY) reported that seven abstracts showcasing data from its cancer research portfolio will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019 (Press release, Incyte, FEB 28, 2019, View Source [SID1234533786]). The meeting will be held March 29 – April 3, 2019, at the Georgia World Congress Center in Atlanta, Georgia.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Accepted abstracts feature data from clinical studies involving Incyte’s anti-PD-1 monoclonal antibody, INCMGA00121, in patients with advanced solid tumors, as well as pre-clinical characterizations of the Company’s oral, small molecule PD-L1 inhibitor program and its PD-L1xCD137 bispecific antibody.

"Data accepted for presentation during the upcoming AACR (Free AACR Whitepaper) Annual Meeting demonstrate our ongoing commitment to advancing innovative research as we seek to bring forward novel therapies for patients with cancer," stated Dashyant Dhanak, Ph.D., Chief Scientific Officer, Incyte. "In particular, we are pleased to present, for the first time at a major medical meeting, early data on our oral PD-L1 inhibitor program—whose lead candidate, INCB86550, recently entered clinical trials."

Key abstracts include:

Clinical

Pharmacodynamic correlates in a phase 1 study of INCMGA00012, a PD-1 antagonistic monoclonal antibody (Abstract #CT085/9, Phase 1 Clinical Trials: Part 3)

Monday, April 1, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 16
Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors(Abstract #LB-268/14, Late-Breaking Research: Experimental and Molecular Therapeutics)

Wednesday, April 3, 2019, 8:00 a.m. – 12:00 p.m. ET, Poster Section 40
Pre-Clinical

Oral Presentations

Novel small-molecule antagonists of the PD-1/PD-L1 axis that mediate cell surface PD-L1 dimerization and internalization (Abstract #4483, Novel Therapeutics)

Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m. ET, Georgia Ballroom 3 – Georgia World Congress Center (Building C)
Preclinical characterization of potent and selective oral PD-L1 small-molecule antagonists (Abstract #4480, Novel Therapeutics)

Tuesday, April 2, 2019, 3:00 p.m. – 5:00 p.m. ET, Georgia Ballroom 3 – Georgia World Congress Center (Building C)
Poster Presentations

A bispecific Fc-silenced IgG1 antibody (MCLA-1452) requires PD-L1 binding to activate CD137 (Abstract #539/3, Therapeutic Antibodies I)

Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 23
An unbiased screen identifies a CD137xPD-L1 bispecific IgG1 antibody with unique T cell activation and binding properties (Abstract #541/5, Therapeutic Antibodies I)

Sunday, March 31, 2019, 1:00 p.m. – 5:00 p.m. ET, Poster Section 23
Characterization of human cancer cell line xenografts in humanized mice (Abstract #1050/1, Human in Mouse)

Monday, April 1, 2019, 8:00 a.m. – 12:00 p.m. ET, Poster Section 4
Full session details and data presentation listings for AACR (Free AACR Whitepaper) 2019 can be found at: View Source!/6812.